Black Diamond Therapeutics, Inc.BDTX

Black Diamond Therapeutics Inc. is a clinical-stage oncology company chasing drugs it has not yet sold, and the latest SEC filings prove the chase is getting expensive. In the first quarter of 2026, the company reported a net loss of $9.0 million, an operating loss of $11.3 million, and negative diluted EPS of $0.16, all while burning $10.2 million in operating cash and watching its cash pile shrink to $30.1 million. The 10-Q for the period ending 31 March 2026 is a ledger of red ink: assets of $132.9 million, liabilities of $28.6 million, and stockholders’ equity of $104.3 million that reads less like a runway and more like a warning.

The company’s website greets visitors with a family photo-son, mother, and father embracing on a porch-paired with the claim that its lead program, BDTX-4876, shows data ‘far exceeding historical benchmarks.’ The image is warm, the science less so. BDTX-4876, an FGFR inhibitor, is a named program with a glossy slide and no human trial success yet, while BDTX-4933, a BRAF program, boasts preclinical data the company last presented in 2023. The company’s May 21, 2026 press release called the figures ‘encouraging,’ a biotech codeword for ‘not yet useful.’

Black Diamond’s SEC filings are thorough but thin on what matters: revenue, guidance, or a path to profit. The 10-Q discloses $7.0 million in R&D spend and $10.2 million in operating cash used but never mentions revenue, guidance, or a clear route to cash generation. The company’s cash and equivalents stand at $30.1 million as of 31 March 2026, a figure that would cover roughly six months of rent in Cambridge, Massachusetts, where the thermostat tends toward ‘startup chic’ rather than ‘profitable scale.’

The company trades as BDTX on Nasdaq, a venue that handles liquidity with ease but cannot magically turn a clinical-stage oncology outfit into a revenue machine. The stock’s daily volume is healthy enough for algorithmic noise, but the underlying business remains a cash-burning research project with a glossy wrapper and a thin evidence base. For a real-time chart route, the SEC filings and the Nasdaq quote page are the only sources that currently offer hard data; any attempt to overlay technical levels would be speculative and is therefore omitted here.

The company’s latest Schedule 13G/A shows one investor increasing its stake to 10.8% on 8 July 2026, a vote of confidence that feels suspiciously like a lifeline rather than a conviction call. Six insiders filed Form 4s on 29 June 2026, each reporting transactions that collectively look like a group exercise in wealth signalling rather than genuine alignment. The board may consist of biotech veterans, but the only thing expanding rapidly is the distance between the cash burn and the next financing event.

The company’s patient-facing pages feature a family photo and a promise of transformational therapies, but the clinical trials page lists recruiting, active, and completed studies with the same enthusiasm as a graveyard’s occupancy chart. The clinical-trial pipeline is real, but the patients inside it are not yet on the drug. The company’s own filings admit to a quarterly cash burn of $10.2 million, a figure that outpaces the decor on its website and the hope in its press releases. The human scene-the family photo-is a reminder that behind every pipeline slide there are patients waiting, but the balance sheet is speaking a different language, one that currently translates as ‘more money needed.’

The company’s submissions JSON on EDGAR reveals a steady stream of 8-Ks and 10-Qs but zero 10-Ks since 2023, a gap that in plain English means the auditors still haven’t signed off on the annual accounts. The companyfacts JSON confirms the same cash burn and loss figures, while the clinical trials page lists studies with the same enthusiasm as a waiting room with no patients inside. The only thing clearer than the science is the arithmetic: $30.1 million in cash, $10.2 million burned last quarter, and no revenue in sight.